Biodistribution and Clearance of 125I-labeled C-reactive Protein and 125I-labeled Modified C-reactive Protein in CD-1 Mice
Overview
Authors
Affiliations
Iodinated forms of C-reactive protein (CRP), soluble modified CRP (mCRP-sol), and suspended mCRP (mCRP-susp) were injected iv into CD-1 mice, for analysis of their pharmacokinetics (PK) and biodistribution (BD). The plasma half-life of 125I-CRP, measured as 4.7 hr, agrees closely with previous reports. The PK and BD characteristics for 125I-mCRP-sol and 125I-mCRP-susp were comparable to each other and were distinctly different from those measured for CRP. Whereas approximately 50% of 125I-CRP was recoverable from plasma 5 min after injection, only approximately 5% of 125I-mCRP was similarly recoverable. The estimated volume of distribution at steady state calculated for either form of 125I-mCRP was approximately 10-fold greater than that calculated for 125I-CRP (23. 4-27.6 and 2.4 ml, respectively). The estimated mean residence times for 125I-mCRP were approximately 2 times longer than that measured for 125I-CRP (9.5-11.5 hr, compared with 4.9 hr). At both 4- and 24-hr time points, substantial amounts of 125I-mCRP were selectively distributed in the bone marrow. At 24 hr, approximately 25% of the injected 125I-mCRP-sol and 125I-mCRP-susp was localized to the bone marrow (corresponding to 92% of injected dose/g of tissue). At this time point, only 8% (or 27%/g) of 125I-CRP was localized to the bone marrow. Overall, the data presented indicate that 1) mCRP has PK and BD characteristics distinct from those of CRP; 2) injected mCRP, although it is rapidly cleared from the general circulation, accesses large body areas and is selectively localized to the bone marrow; and 3) all forms of CRP appear to be excreted in the urine.
Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.
Ullah N, Wu Y Cell Biochem Biophys. 2022; 80(4):595-608.
PMID: 35997934 DOI: 10.1007/s12013-022-01089-x.
Intra-subunit Disulfide Determines the Conversion and Structural Stability of CRP Isoforms.
Zhang C, Tan Y, Zhou H, Ge Z, Feng J, Lv G Inflammation. 2019; 43(2):466-477.
PMID: 31760526 DOI: 10.1007/s10753-019-01130-x.
Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.
Braig D, Nero T, Koch H, Kaiser B, Wang X, Thiele J Nat Commun. 2017; 8:14188.
PMID: 28112148 PMC: 5264208. DOI: 10.1038/ncomms14188.
Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.
Thiele J, Zeller J, Bannasch H, Stark G, Peter K, Eisenhardt S Mediators Inflamm. 2015; 2015:372432.
PMID: 26089599 PMC: 4451254. DOI: 10.1155/2015/372432.
Gang T, Hanley G, Agrawal A Infect Immun. 2015; 83(5):1845-52.
PMID: 25690104 PMC: 4399050. DOI: 10.1128/IAI.03058-14.